Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GLP1 Diabetes Showdown Nears As Lyxumia Gets Green Light In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

The EU's Committee for Medicinal Products for Human Use has recommended two Sanofi products - the diabetes therapy Lyxumia and the colorectal cancer drug Zaltrap – while also backing the first vaccine in Europe for meningitis B, Novartis' Bexsero.

You may also be interested in...



Zealand Pharma Lands Novel Eli Lilly R&D Deal In Diabetes And Obesity

Zealand Pharma has landed another major partnership, this time with Lilly to help develop what the Danish biotech hopes will be a novel, best-in-class treatment for obesity and type 2 diabetes. The process will take years but could lead to other innovative drug deals with the U.S. drug maker.

New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP

Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.

Market For Sanofi And Regeneron’s Zaltrap Could Be Limited

Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel